BNP/CALL/ASTRAZENECA/12000/0.1/20.06.25 | Market Closed - Boerse Frankfurt Warrants 11:21:09 2024-05-17 EDT | ||
| 1.75 EUR | -0.57% |
|
| Current month | +1.74% | ||
| 1 month | +66.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.75 | -0.57% |
| 24-05-16 | 1.76 | -3.83% |
| 24-05-15 | 1.83 | -2.66% |
| 24-05-14 | 1.88 | -1.05% |
| 24-05-13 | 1.9 | -4.04% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 11:21 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC5CAV |
| ISIN | DE000PC5CAV9 |
| Date issued | 2024-02-20 |
| Strike | 12,000 p |
| Maturity | 2025-06-20 (399 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2 € |
|---|---|
| Lowest since issue | 0.59 € |
| Spread | 0.01 € |
| Spread % | 0.57% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Warrants
- Warrant
